The University of Chicago Header Logo

Connection

Rita Nanda to Triple Negative Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Rita Nanda has written about Triple Negative Breast Neoplasms.
Rita Nanda
Connection Strength
6.032
Triple Negative Breast Neoplasms
  1. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
    View in: PubMed
    Score: 0.732
  2. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2022 Jun; 31(6):531-548.
    View in: PubMed
    Score: 0.694
  3. Novel therapies for triple-negative breast cancer. Clin Adv Hematol Oncol. 2020 Dec; 18(12):799-801.
    View in: PubMed
    Score: 0.654
  4. Atezolizumab for the treatment of breast cancer. Expert Rev Anticancer Ther. 2020 03; 20(3):151-158.
    View in: PubMed
    Score: 0.620
  5. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016 07 20; 34(21):2460-7.
    View in: PubMed
    Score: 0.476
  6. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.
    View in: PubMed
    Score: 0.206
  7. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
    View in: PubMed
    Score: 0.194
  8. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4.
    View in: PubMed
    Score: 0.193
  9. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.192
  10. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. JCO Precis Oncol. 2023 04; 7:e2200317.
    View in: PubMed
    Score: 0.192
  11. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147.
    View in: PubMed
    Score: 0.189
  12. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
    View in: PubMed
    Score: 0.176
  13. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.171
  14. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
    View in: PubMed
    Score: 0.171
  15. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 09 01; 6(9):1410-1415.
    View in: PubMed
    Score: 0.161
  16. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 05 01; 26(9):2111-2123.
    View in: PubMed
    Score: 0.153
  17. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82.
    View in: PubMed
    Score: 0.143
  18. First international TNBC conference meeting report. Breast Cancer Res Treat. 2018 Jun; 169(3):407-412.
    View in: PubMed
    Score: 0.135
  19. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 03 20; 36(9):884-890.
    View in: PubMed
    Score: 0.134
  20. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.121
  21. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21(12):2771-9.
    View in: PubMed
    Score: 0.110
  22. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Jun 15; 21(12):2722-9.
    View in: PubMed
    Score: 0.110
  23. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66.
    View in: PubMed
    Score: 0.105
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.